← Back to Clinical Trials
Recruiting NCT07332312

NCT07332312 A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Indian and Alaska Native Cancer Patients Living in Rural California

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07332312
Status Recruiting
Phase
Sponsor University of Southern California
Condition Hematopoietic and Lymphatic System Neoplasm
Study Type INTERVENTIONAL
Enrollment 71 participants
Start Date 2026-04-17
Primary Completion 2027-11-13

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
DiscussionDiscussionEducational Intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 71 participants in total. It began in 2026-04-17 with a primary completion date of 2027-11-13.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This clinical trial develops and tests whether a culturally informed patient navigation program, Community-Focused Patient Navigation (CFPN), works to reduce delays between diagnosis and treatment in American Indian and Alaska Native (AIAN) cancer patients living in rural California. AIAN communities face some of the most severe cancer disparities in the United States, including higher death rates, later-stage diagnoses, and limited access to timely, culturally responsive care. This may be due to barriers such as rural isolation, divided referral systems, or a lack of trust in mainstream healthcare systems. Patient navigation is a care delivery model designed to guide a patient through the healthcare system and address the barriers that prevent patients from accessing timely and effective care. The CFPN program is culturally tailored and designed with AIAN communities in mind. The program provides the patient with a treatment plan based on the patient's unique needs, goals, and barriers. This may be an effective way to reduce delays between diagnosis and treatment in AIAN cancer patients living in rural California.

Eligibility Criteria

Inclusion Criteria: * CAB: Self-identify as AIAN or have experience working with the AIAN community * CAB: Are 18 years or older * CAB: Live within Toiyabe Indian Health Program (TIHP) catchment area(s) * CAB: Are either a cancer patient/survivor/caregiver and/or a family member of an individual(s) affected by cancer, OR a Board member (ex: Tribal Health Board or Elders Board) * FOCUS GROUP: Self-identify as AIAN or a family member of an AIAN individual affected by cancer * FOCUS GROUP: Are 18 years or older * FOCUS GROUP: Live within TIHP catchment area(s) * FOCUS GROUP: Are either a cancer patient/survivor/caregiver and/or a family member of an individual(s) affected by cancer, OR a Board member (ex: Tribal Health Board or Elders Board) * KII: Be a TIHP healthcare staff member * KII: Be 18 years or older * KII: Work with AIAN cancer patients in TIHP catchment area * CFPN PROGRAM IMPLEMENTATION: Have any type of cancer, are in any treatment stage along the cancer continuum * CFPN PROGRAM IMPLEMENTATION: Self-identify as AIAN or be a TIHP patient * CFPN PROGRAM IMPLEMENTATION: Live in the TIHP service area * CFPN PROGRAM IMPLEMENTATION: Receive cancer-related services from TIHP Exclusion Criteria: * FOCUS GROUP: Individual with no experience with cancer either as a patient or know someone who is/was a cancer patient at TIHP * CFPN PROGRAM IMPLEMENTATION: Not a TIHP patient * CFPN PROGRAM IMPLEMENTATION: Does not currently have cancer or has not previously had cancer

Contact & Investigator

Principal Investigator

Claradina Soto

PRINCIPAL INVESTIGATOR

University of Southern California

Frequently Asked Questions

Who can join the NCT07332312 clinical trial?

This trial is open to participants of all sexes, studying Hematopoietic and Lymphatic System Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07332312 currently recruiting?

Yes, NCT07332312 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Southern California to inquire about joining.

Where is the NCT07332312 trial being conducted?

This trial is being conducted at Bishop, United States, Los Angeles, United States.

Who is sponsoring the NCT07332312 clinical trial?

NCT07332312 is sponsored by University of Southern California. The principal investigator is Claradina Soto at University of Southern California. The trial plans to enroll 71 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology